CHEST 2017: American College of Chest Physicians Unveils New Lung Cancer Screening Guidelines

Low-dose computed tomography (CT) screening for lung cancer has become standard practice, mostly due to the results of the National Lung Screening Trial. Related evidence continues to evolve, informing the benefits and risks of low-dose CT in clinical practice. Mazzone et al presented new evidence on lung cancer screening with low-dose computed tomography and provided updated recommendations at CHEST 2017. The recommendation summary along with remarks for each recommendation and abstract can be viewed on the website of the American College of Chest Physicians, and a forthcoming complete manuscript will be published in the journal CHEST.

Key recommendations and shifts from previous guidelines include:

  • For asymptomatic smokers and former smokers aged 55 to 77 years who have smoked 30 pack-years or more and either continue to smoke or have quit within the past 15 years, annual screening with low-dose CT should be offered.
  • For asymptomatic smokers and former smokers who do not meet the smoking and age criteria in the latter recommendation but are deemed to be at high risk of having/developing lung cancer based on clinical risk prediction calculators, low-dose CT screening should not be routinely performed.
  • For individuals who have accumulated fewer than 30 pack-years of smoking or are younger than age 55 or older than age 77, or have quit smoking more than 15 years ago, and do not have a high risk of having/developing lung cancer based on clinical risk prediction calculators, low-dose CT screening should not be performed.
  • For individuals with comorbidities that adversely influence their ability to tolerate the evaluation of screen-detected findings, to tolerate treatment of an early-stage screen-detected lung cancer, or that substantially limit their life expectancy, low-dose CT screening should not be performed.

“This guideline differs from our previous guideline, as we went beyond discussing harms and benefits,” said Peter Mazzone, MD, FCCP, Guideline Chair. “We addressed implementation of low-dose CT screening, including who to screen, how to identify appropriate patients for screening, how to conduct a shared-decision-making visit, how to perform low-dose CT, and how to manage abnormal findings.”  

“The potential benefit of cancer screening to reduce the number of cancer-related deaths must be balanced with potential harms of screening,” said Gerard Silvestri, MD, FCCP, Guideline Panelist and CHEST Immediate Past President. “Current evidence suggests that even within groups at high risk of developing a cancer, only a small fraction of those screened will benefit, while everyone screened is exposed to potential harms, including physical and psychosocial consequences of identifying and subsequently evaluating a screen-detected nodule, radiation exposure, overdiagnosis, and overtreatment. For this reason, our recommendations for screening have evolved to be even more selective and specifically target those highest-risk populations. The evidence currently does not support widespread adoption of lung cancer screening outside of those patients described in our recommendations.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.